MedPath

Trusted Messenger Intervention

Not Applicable
Terminated
Conditions
Vaccine Hesitancy
Registration Number
NCT05167422
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Brief Summary

The objective of this pilot study is to develop and evaluate test a trusted messenger intervention targeting vaccine hesitancy in patients on an inpatient psychiatric hospital setting with both acute and chronic patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
2
Inclusion Criteria
  • Able and willing to give verbal informed consent to participate in the study or able to assent with guardian consent
  • Expected to remain in the hospital for the duration of the study
  • Mental health diagnosis Demographics
  • Male, female, or transgender (no exclusion criteria based on gender or sexual orientation)
  • Ages 18 or older
  • Any race or ethnicity
  • English speaking
Exclusion Criteria
  • Cognitive impairment sufficient to interfere with participant's ability to provide assent
  • People who are non-English speakers or who have major visual or hearing impairment will be excluded given the need to converse with the Trusted Messenger verbally
  • People who have received any of the available forms of the COVID-19 vaccine, or those with a medical exemption for receiving the vaccine.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Vaccine acceptance- This will be measured using the COVID Vaccine Hesitancy QuestionnaireParticipant is willing to receive the vaccine by the end of week 6 of participation from baseline.

The participant is willing to receive the COVID-19 vaccine

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

New Hampshire Hospital

🇺🇸

Concord, New Hampshire, United States

New Hampshire Hospital
🇺🇸Concord, New Hampshire, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.